These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27685641)

  • 1. Firms' compliance with complex regulations.
    Mendoza JP; Dekker HC; Wielhouwer JL
    Law Hum Behav; 2016 Dec; 40(6):721-733. PubMed ID: 27685641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Firm's compliance behaviour towards food fortification regulations: Evidence from oil and salt producers in Bangladesh.
    Saha A; Guariso D; Mbuya MNN; Ebata A
    Food Policy; 2021 Oct; 104():102143. PubMed ID: 34720344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Cooperative Compliance on Firms' Tax Risk, Tax Risk Management and Compliance Costs.
    Eberhartinger E; Zieser M
    Schmalenbach Z Betriebswirtsch Forsch; 2021; 73(1):125-178. PubMed ID: 34803211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling the Effectiveness of Agency Cost and Firms' Size as Moderators Between CSR Disclosure and Firms' Growth.
    Akram A; Tang Y; Tariq J
    Front Psychol; 2020; 11():1624. PubMed ID: 32903572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Environmental compliance: The good, the bad, and the super green.
    Wu J
    J Environ Manage; 2009 Aug; 90(11):3363-81. PubMed ID: 19573979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evasion of "mandatory" social health insurance for the formal sector: evidence from Lao PDR.
    Alkenbrack S; Hanson K; Lindelow M
    BMC Health Serv Res; 2015 Oct; 15():473. PubMed ID: 26482171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors.
    Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J
    BMC Health Serv Res; 2006 May; 6():63. PubMed ID: 16734916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental pollution policy of small businesses in Nigeria and Ghana: extent and impact.
    Efobi U; Belmondo T; Orkoh E; Atata SN; Akinyemi O; Beecroft I
    Environ Sci Pollut Res Int; 2019 Jan; 26(3):2882-2897. PubMed ID: 30499086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Customers' Perceptions of Compliance with a Tobacco Control Law in Restaurants in Hanoi, Vietnam: A Cross-Sectional Study.
    Dang AK; Tran BX; Nguyen LH; Do HT; Nguyen CT; Fleming M; Le HT; Le QNH; Latkin CA; Zhang MWB; Ho RCM
    Int J Environ Res Public Health; 2018 Jul; 15(7):. PubMed ID: 29996487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
    Sinclair P; Kable A; Levett-Jones T
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceived Distributive Fairness of EU Transfer Payments, Outcome Favorability, Identity, and EU-Tax Compliance.
    Hartner M; Rechberger S; Kirchler E; Wenzel M
    Law Policy; 2011 Jan; 33(1):60-81. PubMed ID: 21412442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small firms' actions in two areas, and exchange premium and enrollment impact.
    Eibner C; Price CC; Vardavas R; Cordova A; Girosi F
    Health Aff (Millwood); 2012 Feb; 31(2):324-31. PubMed ID: 22323162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference pricing and firms' pricing strategies.
    Miraldo M
    J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Language of Fairness: how Cross-Linguistic Norms in Spanish and English Influence Reactions to Unfair Treatment.
    Birk SJ; Kausel EE
    Span J Psychol; 2016 Nov; 19():E79. PubMed ID: 27841105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating firms' R&D performance using best worst method.
    Salimi N; Rezaei J
    Eval Program Plann; 2018 Feb; 66():147-155. PubMed ID: 29091790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance costs and productivity: an approach from working hours.
    Morikawa M
    J Regul Econ; 2023 Jun; ():1-21. PubMed ID: 37363073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marketing innovations during a global crisis: A study of China firms' response to COVID-19.
    Wang Y; Hong A; Li X; Gao J
    J Bus Res; 2020 Aug; 116():214-220. PubMed ID: 32501308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Micro-simulation of firms' heterogeneity on pollution intensity and regional characteristics].
    Zhao N; Liu Y; Chen JN
    Huan Jing Ke Xue; 2009 Nov; 30(11):3190-5. PubMed ID: 20063728
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.